These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22010189)

  • 1. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.
    Sibbing D; Bernlochner I; Kastrati A; Paré G; Eikelboom JW
    Circ Cardiovasc Interv; 2011 Oct; 4(5):505-13; discussion 513. PubMed ID: 22010189
    [No Abstract]   [Full Text] [Related]  

  • 2. Current status of clopidogrel pharmacogenomics.
    Giusti B; Gori AM; Marcucci R; Abbate R
    Pharmacogenomics; 2012 Nov; 13(15):1671-4. PubMed ID: 23171330
    [No Abstract]   [Full Text] [Related]  

  • 3. Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention.
    Paré G; Eikelboom JW; Sibbing D; Bernlochner I; Kastrati A
    Circ Cardiovasc Interv; 2011 Oct; 4(5):514-21; discussion 521. PubMed ID: 22010190
    [No Abstract]   [Full Text] [Related]  

  • 4. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
    Price MJ; Tantry US; Gurbel PA
    Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacogenomics of clopidogrel.
    Levitt MR; Osbun JW; Kim LJ
    World Neurosurg; 2012; 77(3-4):406-7. PubMed ID: 22366366
    [No Abstract]   [Full Text] [Related]  

  • 7. The P2Y12 receptor: no active metabolite, no party.
    Patrono C
    Nat Rev Cardiol; 2009 Apr; 6(4):271-2. PubMed ID: 19352330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A current problem for regulators. Clopidogrel and pharmacokinetics].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):360-7. PubMed ID: 19572363
    [No Abstract]   [Full Text] [Related]  

  • 9. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.
    Smock KJ; Saunders PJ; Rodgers GM; Johari V
    Am J Hematol; 2011 Dec; 86(12):1032-4. PubMed ID: 21812020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptance of high platelet reactivity as a risk factor: now, what do we do about it?
    Gurbel PA; Tantry US
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1008-10. PubMed ID: 20965457
    [No Abstract]   [Full Text] [Related]  

  • 11. Clopidogrel: to test or not to test? That is the question--still.
    Cannon CP
    Clin Chem; 2011 May; 57(5):659-61. PubMed ID: 21402801
    [No Abstract]   [Full Text] [Related]  

  • 12. Clopidogrel resistance: pharmacokinetic or pharmacogenetic?
    Ford NF
    J Clin Pharmacol; 2009 May; 49(5):506-12. PubMed ID: 19246723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacogenetics of clopidogrel and its clinical significance].
    Panchenko EP; Komarov AL
    Kardiologiia; 2012; 52(9):44-52. PubMed ID: 23098546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics: Point-of-care genetic testing--a new frontier explored.
    Barrett PM; Topol EJ
    Nat Rev Cardiol; 2012 May; 9(6):315-6. PubMed ID: 22547169
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations.
    Angiolillo DJ; Ueno M
    JACC Cardiovasc Interv; 2011 Apr; 4(4):411-4. PubMed ID: 21511220
    [No Abstract]   [Full Text] [Related]  

  • 17. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 18. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.
    Peters BJ; Harmsze AM; ten Berg JM; Maitland-van der Zee AH; Tjoeng MM; de Boer A; Deneer VH
    Pharmacogenomics; 2011 Feb; 12(2):141-4. PubMed ID: 21332306
    [No Abstract]   [Full Text] [Related]  

  • 19. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
    Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
    Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents.
    Gurbel PA; Tantry US
    Circulation; 2012 Mar; 125(10):1276-87; discussion 1287. PubMed ID: 22412089
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.